Figure 6
Effect of TAK165 and ATRA on the MEK pathway.
(a) Western blot analysis of MAPK signaling in the HL60 and NB4 cells. The cells were treated withTAK165 (100 nM for HL60, 50 nM for NB4) and ATRA (1 μM for HL60, 2 nM for NB4) for 3 days. (b,c) CD11b expression in the HL60 and NB4 cells. The cells were treated with TAK165 (100 nM for HL60, 50 nM for NB4) and ATRA (1 μM for HL60, 2 nM for NB4) in the presence of vehicle or MAPK inhibitors (20 μM SB203580 (p38 inhibitor), 20 μM sp600125 (JNK inhibitor), 10 μM PD98059 (MEK inhibitor), 5 μM U0126 (MEK inhibitor) for 3 days. The data presented are the mean ± SD. ***p < 0.001.n.s, p > 0.05. (d) Western blot analysis of p-STAT1 (Tyr701 and Ser727), STAT1 and the MEK signal pathway in the NB4 cells. The cells were treated with 50 nM TAK165 and 2 nM ATRA in the presence of vehicle or MAPK inhibitors (10 μM PD98059 or 5 μM U0126) for 3 days.
